February 6, 2019

The Early Diagnosis of Alzheimer’s Disease: A Patient-centered Conversation with the Care Team

Virtual 2021 European Academy of Neurology (EAN) Congress

Optimizing Management for Patients with Alzheimer’s Disease

In the closing section, Professor Frisoni first discusses considerations for disclosing an early diagnosis of AD to patients and their families. He then outlines major healthcare system constraints for improving the management of AD, including lack of specialist capacity and barriers to accessing diagnostic and follow-up services.

Key Learning Objectives from Biogen’s EAN 2021 Symposium:

  • Address the complexities around diagnosis and management of AD, including how cognitive and functional assessments may support the early diagnosis of AD
  • Gain insights into the use of diagnostic biomarkers and the impact these could have on the patient journey
  • Discuss current and prospective measures that could be undertaken to allow the timely diagnosis and management of individuals with AD, in the context of current healthcare infrastructure

Disclosure: All panelists received honoraria from Biogen for participation in this symposium.

Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.